Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2 CAR-T cell therapy (YaKe Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HER2 CAR-T cell therapy is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by YaKe Biotechnology for the treatment of HER2-positive solid tumors, specifically breast cancer. The therapy involves the genetic modification of a patient's T cells to express a CAR that specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2/ErbB2). Upon re-infusion into the patient, these engineered T cells recognize and bind to HER2-expressing malignant cells, triggering T-cell activation, proliferation, and targeted cytotoxicity. The program is currently in the preclinical stage of development.
- Other names
- HER2-ErbB2-CAR-T cell therapyHER-2-ErbB2-CAR-T cell therapyHER 2-ErbB2-CAR-T cell therapyHER2 CAR-THER-2 CAR-THER 2 CAR-TErbB2 CAR-TErbB-2 CAR-TErbB 2 CAR-T
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2 CAR-T cell therapy (YaKe Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2 CAR-T cell therapy (YaKe Biotechnology).